Pfizer May Enjoy Blockbuster Cardiomyopathy Success With Tafamidis

Although tafamidis has been stalled at FDA for transthyretin-mediated polyneuropathy, Pfizer may have found a different path toward US approval with cardiovascular outcomes data in cardiomyopathy.